人可溶性血管内皮生长因子受体1抑制白血病细胞增殖探究.docVIP

人可溶性血管内皮生长因子受体1抑制白血病细胞增殖探究 　【摘要】 本研究通过体外实验探讨人可溶性血管内皮生长因子受体1（sFLT1）对白血病细胞增殖的抑制作用。用RTPCR检测白血病细胞株K562、HL60、U937和骨髓LTCIC VEGF mRNA、VEGFR1（FLT1） mRNA的表达，用流式细胞术检测上述细胞VEGF和VEGFR1(FLT1)的表达，ELISA法检测细胞培养上清中VEGF的含量，将sFLT1加入 K562、HL60白血病细胞株和骨髓LTCIC培养体系中，应用MTT法计算细胞生长的抑制率。结果显示：白血病细胞株K562、HL60、U937和骨髓LTCIC均表达VEGF，以K562表达VEGF量最高。K562和HL60细胞株还表达FLT1，U937细胞和骨髓LTCIC表达的FLT1表达量很低。sFLT1明显抑制白血病细胞株K562及HL60的生长，并且随着sFLT1浓度的增加，其抑制率增加，以用药后48小时抑制作用最明显。结论： sFLT1能够抑制某些白血病细胞株的生长，其抑制效应随用药浓度的增加而增加，而sFLT1对正常骨髓细胞增殖无影响。 【关键词】 VEGF FLT1 白血病细胞 Inhibition of Leukemic Cell Proliferation by Human Soluble VEGFR1 Abstract The current study was purposed to investigate the inhibitory effect of human soluble vascular endothelial growth factor1 (sFLT1) on the proliferation of leukemic cells in vitro. Reverse transcriptionpolymerase chain reaction (RTPCR) was used to detect the VEGF mRNA and VEGFR1（FLT1） mRNA in K562, HL60, U937 leukemic cell lines and bone marrow LTCIC. Flow cytometry was used to detect the VEGF and VEGFR1（FLT1）in all abovementioned cells. VEGF concentrations in the cell culture supernatants were determined by enzymelinked immunosorbent assay (ELISA). Cell proliferation was determined by MTT after adding sFLT1 to K562， HL60 and LTCIC culture system. The result showed that expression of VEGF could be detected in K562,HL60,U937 leukemic cell lines and LTCIC, especially K562, K562 and HL60 cell lines also expressed FLT1, but a little expression was found in U937 and LTCIC. sFLT1 could effectively inhibit the growth of K562 and HL60 cell lines in dosedependent manner. The highest inhibition rate was found at 48 hours after adding sFLT1. It is concluded that sFLT1 can inhibit the growth of some leukemic cell lines, and the inhibition effect enhances as the concentration of the sFLT1 increase, but sFLT 1 not influence the proliferation of normal marrow cells. Key word VEGF; FLT1; leukemic cell 近年来越来越多的证据表明，血管内皮生长因子（VEGF）与白血病的发生、发展、演变及预后相关，它可以促进白血病细胞的